Can Open-Source Drug R&D Repower Pharmaceutical Innovation?

Corporate Strategy, Eli Lilly and Company, Indianapolis, Indiana, USA.
Clinical Pharmacology &#38 Therapeutics (Impact Factor: 7.9). 05/2010; 87(5):534-6. DOI: 10.1038/clpt.2010.26
Source: PubMed


Open-source R&D initiatives are multiplying across biomedical research. Some of them-such as public-private partnerships-have achieved notable success in bringing new drugs to market economically, whereas others reflect the pharmaceutical industry's efforts to retool its R&D model. Is open innovation the answer to the innovation crisis? This Commentary argues that although it may likely be part of the solution, significant cultural, scientific, and regulatory barriers can prevent it from delivering on its promise.

Download full-text


Available from: Bernard H Munos
  • Source
    • "There have been new management models for innovation suggested by scholars: the " transition point model " (Allarakhia & Walsh, 2010), the new paradigm of the firm (Bessant & Francis, 2005), and the " design logic " (Elmquist et al., 2007), and " Efficient Innovation Managerial Model (EIMM) " (Kim, 2012). In practice, the Asian Cancer Research Group (ACRG) gained special attention as open innovation research models: Weigelt (2009), Allarakhia & Walsh (2010), and Munos (2010). On the other hand, there is a further need for new performance measurements of productivity for innovation – measures that do not discourage creativity. "

    Full-text · Article · Jan 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: We are interested in performing reduction operations with distributed memory machines whose interconnection networks are reconfigurable. More precisely, we focus on machines whose interconnection graph can be configured as any graph of maximum degree d. We discuss the best way of interconnecting the p processors as a function of p, d, and some problem- and machine dependent-parameters that characterize the ratio communication/arithmetic for the reduction operation. Experiments on Transputer-based networks are in good accordance with the theoretical results.
    No preview · Article · Jan 1992
  • [Show abstract] [Hide abstract]
    ABSTRACT: Self-assembled GaInNAs quantum dots (QD) were fabricated on GaAs [001] substrate by solid source molecular beam epitaxy (SSMBE) equipped with a RF nitrogen plasma source. The surface morphology was investigated using atomic-force microscopy (AFM), and the photoluminescence (PL) of the QDs was measured at low temperature (5 K). Through these measurements, the effect of indium and nitrogen compositions on the island density, island size, and optical properties were studied. The experiment was carried out with indium and nitrogen composition ranges of 30%-70% and 0.4%-0.8%, respectively. Using high indium composition, an island density of 1×1<sup>01</sup>1/cm<sup>2</sup> was obtained in a single layer of GaInNAs QDs. The AFM results showed that the island size of the QDs is in the range of 20-40 nm with an average height of 5-16 nm and the highest island density of 1×10<sup>11</sup>/cm<sup>2</sup> has been achieved. Low temperature (5 K) photoluminescence (PL) wavelength of 1.10 μm to 1.54 μm was detected from these samples.
    No preview · Conference Paper · Feb 2002
Show more